Publication date: Jul 07, 2025
Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is a growing global health concern, affecting 10-35% of COVID-19 survivors. Characterized by persistent multisystem symptoms lasting beyond 12 weeks, common manifestations include fatigue, dyspnea, chest pain, cognitive impairment, depression, and anxiety. The underlying pathophysiology remains unclear but is likely to involve immune dysregulation, persistent inflammation, endothelial dysfunction, gut dysbiosis, and viral persistence. This review examines the epidemiology, risk factors, and clinical manifestations of long COVID, with a focus on its impact on cardiopulmonary, neurological, and mental health. Therapeutic approaches include pharmacological interventions such as anti-inflammatory agents, antioxidants, neuroprotective drugs, and repurposed medications. Non-pharmacological strategies, such as physical rehabilitation, cognitive therapy, dietary modification, and emerging therapies like stem cell therapy, as well as immunomodulatory approaches, offer promising avenues for recovery. We also highlight ongoing clinical trials evaluating targeted therapies for long-term COVID syndrome. Future research should focus on elucidating the pathophysiological mechanisms, identifying biomarkers, and optimizing personalized treatment strategies for long-term COVID-19 management.
| Concepts | Keywords |
|---|---|
| 12weeks | Anti-oxidants |
| Covid | Dyspnea |
| Fatigue | GUT dysbiosis |
| Inflammopharmacology | Immune dysregulation |
| Viral | Long-COVID syndrome |
| SARS-CoV-2 | |
| Viral persistence |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Long COVID |
| disease | MESH | syndrome |
| disease | MESH | COVID-19 |
| disease | MESH | dyspnea |
| disease | MESH | chest pain |
| disease | MESH | cognitive impairment |
| disease | MESH | depression |
| disease | MESH | anxiety |
| disease | MESH | inflammation |
| disease | MESH | dysbiosis |
| disease | IDO | cell |